

CURRICULUM VITAE

PATRICK M. NEMECHEK, D.O.

Nemechek Health Renewal
4010 Washington, Suite 500
Kansas City, Missouri 64111
816-756-0090
816-756-0120 fax

PRESENT POSITIONS

April 1995 - Present

Founder and Medical Director
Nemechek Health Renewal
Kansas City, Missouri

June 1999 - Present

Co-Investigator
HIV Research Network
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services

HONORS AND AWARDS

June 1999

Selected as one of 18 clinical sites to participate in the HIV Research Network, Managed by the Center for HIV Quality Care of Johns Hopkins Medical Center, and funded by AHRQ.

November 1997

Nominated as one of the top AIDS treating physicians in the United States by POZ Magazine.

April 1996

Choose as Site of Clinical Excellence and Case Study for "INTEGRATED PATIENT CARE: Managing Health Care Costs, Maximizing Health Care Value and Quality". A Study sponsored by Bristol-Myers Squibb Company & KPMG Peat Marwick LLP.

June 1989 - June 1990

Chief Resident, Internal Medicine, U.C.L.A. School of Medicine

May 1989

Robert S. Mosser Award for Excellence in Internal Medicine, U.C.L.A. School of Medicine

February 1990

Abstract accepted for American College of Physicians Annual Associates Scientific Competition

PRIOR SELECTED EXPERIENCE

January 2000 – December 2000

Chairman
Department of Medicine
Overland Park Regional Medical Center
Overland Park, Kansas

June 1994 – May 1999

Editorial Advisory Board
“Prescriber’s Letter”
Stockton, California

June 1997 – December 1998

Medical Review Board
Serostim Continuation Treatment Program
National Organization for Rare Disorders
Washington, D.C.

February 1995 - February 1997

Medical Director
HIV Inpatient Unit
Medicalodge East of Kansas City
Kansas City, Kansas

July 1993 - November 1995

Assistant Medical Director,
Director of Physician Recruiting
Center for Special Immunology,
Irvine, California

May 1991 - June 1992

Founding Medical Director
Chairman, Board of Directors,
Bakersfield AIDS Foundation
Bakersfield, California

June 1990 - July 1992

Clinical Faculty,
UCLA, School of Medicine
Kern Medical Center
Bakersfield, California

CERTIFICATION

Board Certified:

Internal Medicine, A.B.I.M
September 1992

Specialty Certification:

HIV Medicine, AAHIVM
February 2002

EDUCATION

August 1983 - June 1987

Doctor of Osteopathy
University of Health Sciences
Kansas City, Missouri

POST GRADUATE TRAINING

June 23, 1987 - June 22, 1988	Internship in Internal Medicine U.C.L.A. Kern Medical Center Bakersfield, California
June 23, 1988 - June 24, 1990	Residency in Internal Medicine U.C.L.A. Kern Medical Center Bakersfield, California
January 1996	FDA & I.D.S.A. Sponsored Clinical Trials Training Program

PUBLICATIONS

1. "Risk of Coccidioidomycosis Meningitis Associated with Pregnancy", Nemechek P, Johnson R. abstract, *Proceedings of the 32nd Annual Coccidioidomycosis Study Group Meeting*, April 1989.
2. "Coccidioidomycosis Meningitis and Pregnancy: Presentation of Five Cases and a Review of the Literature." Nemechek P, Accepted for presentation at the ACP Annual Associates Scientific Competition; Newport Beach, California, 1990.
3. "Are Parental Anabolic Steroid Users the Next Potential Risk Group for Infection with the Human Immunodeficiency Virus?" Nemechek P., *NEJM*, 1991; 325: pg. 357.
4. "Radiation Recall Associated with Vinblastine in a Patient Treated for AIDS-Associated Kaposi Sarcoma", Nemechek P, Corder M, *Cancer* 1992, Sept (70); 6:1605-6.
5. "Psychoneuroimmunology: A relationship between stress and disease." Nemechek P, Shanti Newsletter; December 1993.
6. "Conversion of Patients with Chronic Meningitis Due to *Coccidioides immitis* from Intrathecal Amphotericin B to Fluconazole". Nemechek P, Accepted for abstract & presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapeutics; Anaheim, California, October 1992.
7. "A Rare Cause of Visual Loss in AIDS Patients: Central Retinal Vein Occlusion". Nemechek P, Ismail Y, Arsura E. *Br J Ophthalmol* 1993 Sept;77(9):600-1.
8. "Prevalence of Nutritional Deficiencies in Patients with HIV-1 Infection." Nemechek P, Tomaka F, Cimoch P Reiter W, et al. Abstract; Tenth International Conference on AIDS, August 1994.
9. "Antibody Response to Pneumococcal Vaccination in HIV-1 Infected Patients". Nemechek P, Cimoch P, Loss S, et al. Abstract; Tenth International Conference on AIDS, August 1994.
10. "Symptomatic *Mycobacterium avium* Complex (MAC) Sinusitis in Patients with AIDS". Nemechek P, Cimoch P, Reisman B. Abstract; 34th Interscience Conference on Antimicrobial Agents and Chemotherapeutics; October 1994.
11. "Fluconazole Therapy in Coccidioidal Meningitis Maintained with Intrathecal Amphotericin B". Perez JA, Nemechek PM et al. *Arch Int Med* 1995 Aug; 7(21): 1665-1668.

12. "A Comparison of Relative Total versus Free Serum Testosterone Levels for the Diagnosis of Hypogonadism in Patients with HIV or AIDS." Nemechek P, Severson K. Abstract, Eleventh International Conference on AIDS, July 1996.
13. "A Correlation Between Classical Interpretation of ACTH-Stimulation Adrenal Stimulation Results and the Clinical Response to Corticosteroids in Patients with CDC Class III AIDS Diagnosis." Nemechek P, Wahl D, Sakuvich L. Abstract, Eleventh International Conference on AIDS, July 1996.
14. "Reduction in Hospital Length of Stay and Associated Costs through the Utilization of a Comprehensive HIV Outpatient Program." Nemechek P, Sackuvich L. Abstract, Ninth National AIDS Update Conference, March 1997.
15. "Maintenance of Body Cell Mass (BCM) and Phase Angle (PA) After Discontinuation of Recombinant Human Growth Hormone (r-hGH; Serostim)." Nemechek P, Sackuvich L, Zachovich P, Stolifer J. Abstract, Second International Conference on AIDS Wasting and Nutrition, April 1997.
16. "Measurement of Body Weight and Body Cell Mass in Patients Receiving Highly Active Antiretroviral Therapy." Berger, Nemechek et al. Abstract, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1997.
17. "Factors Related to Adherence (ADH) with Protease Inhibitors." Nemechek P, Conry M, Westerfelt A, Eicher B, Wine Chase G. Abstract, Twelfth International Conference on AIDS, July 1998.
18. "Increased Urinary Frequency (UF) Secondary to Urinary Retention (UR) in HIV+ males and Treatment with Doxazosin." Nemechek P. Abstract, Twelfth International Conference on AIDS, July 1998.
19. "A Retrospective Study on the Effect of Smoking on Total Body Weight (TBW) and Body Cell Mass (BCM)." Nemechek P, Stolifer J. Abstract, Twelfth International Conference on AIDS, July 1998.
20. "Preservation of Restored Body Cell Mass (BCM) and Phase Angle after Discontinuation of Human Growth Hormone (r-hGH; Serostim)." Nemechek P, Stolifer J, Sackuvich L. Abstract, Twelfth International Conference on AIDS, July 1998.
21. "A Survey Evaluating Pharmacy-related Resources and their Relation to Drug Adherence." Nemechek P, Tritle D. Abstract, Twelfth International Conference on AIDS, July 1998.
22. "Short Term Human Growth Hormone Therapy for HIV-Associated Wasting." Nemechek P. AIDS Patient Care and STDs, 13:7, 1999.
23. "Treatment Guidelines for HIV-Associated Wasting". Nemechek P, Gottlieb M, Polsky B. Mayo Clin Proc (United States), Apr 2000, 75(4) p386-94.
24. "Mammalian Cell-Derived Recombinant Human Growth Hormone (r-hGH[m]) Imparts A Durable and Reproducible Effect on Body Weight in Patients with AIDS Wasting." PM Nemechek, H Landy, P Gaccione. Abstract, Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, UK/ October 22-26, 2000.
25. "CD4 Lymphocyte and Viral Load Response to Structured Intermittent Therapy within a Private Medical Practice Specializing in HIV Care." PM Nemechek, JR Long. Submitted to the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February 24-28, 2002.
26. "Hospital and Outpatient Health Services Utilization Among HIV-Infected Patients in Care in 1999." The HIV Research Network (including PM Nemechek). JAIDS, 30:21-26, 2002.

RESEARCH ACTIVITIES

1. Principle Investigator: Oral Fluconazole vs. Intrathecal Amphotericin B in the Treatment of Chronic Coccidioidal Meningitis. Pfizer, June 1990.
2. Principle Investigator: A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) versus Zidovudine (ZDV) in Patients with AIDS or Advanced ARC; Hoffman-La Roche Corporation, Protocol N3300, July, 1989.
3. Principle Investigator: Treatment IND Protocol for the Use of Videx (ddI) in Patients with AIDS or ARC; Bristol Meyers Corporation, Protocols 454-999-001 and 454-999-002, October, 1989.
4. Principle Investigator: Dideoxycytidine (Ro 24-2027), An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients with AIDS or Advanced ARC who previously Demonstrated Intolerance to Zidovudine (ZDV) in Protocol N3300 or N3492; Hoffman-La Roche Corporation, Protocol N 3526, September, 1990.
5. Co-Investigator: An Open-Label Trial to Evaluate the Safety and Efficacy of Clarithromycin in the Treatment of Disseminated *Mycobacterium avium* Complex (MAC) Infection in AIDS Patients; Abbott Lab., Protocol M91-577 and Protocol M91--577A, Aug 1991.
6. Co-Investigator: Treatment IND and Open-Label Protocol for 566C80 Therapy of *Pneumocystis carinii* Pneumonia. Burroughs Welcome Company, November, 1991.
7. Co-Investigator: A Six Month Study of Intensive Nutritional Supplementation in HIV-Infected Individuals with Early Signs of Malnutrition and Wasting; McGaw Incorporated, Protocol 89105, November, 1992.
8. Co-Investigator: A Phase II Multicenter Study of the Safety and Efficacy of MNrgp/HIV-1 Vaccine Compared with Placebo in HIV-1 Seropositive Subjects with CD4 Cell Counts Greater than 600 Cells/cu mm. Genetech Incorporated, Study VC346g, January, 1993.
9. Co-Investigator: A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (900 mg) or Rifabutin (600 mg) or Placebo. Adria Laboratories, Study No. 087250-006, April, 1993.
10. Co-Investigator: Study of the Activity of THF-2 on HIV Load in HIV Positive Individuals with CD4+ Cell Counts in the Range of 200-500/uL. Adria Laboratories, Protocol 112010-999, June, 1993.
11. Co-Investigator: A Randomized Comparative Study of Delavirdine (U-90152S) in Combination with Didanosine (ddI) versus ddI Alone in HIV-1 Infected Individuals with a CD4 Count of Less Than 300/cu mm. The Upjohn Company, Protocol M/3331/0017, September, 1993.
12. Co-Investigator: A Pilot Study of the Efficacy of 5 to 10 Million Units Daily of Interferon Alfa-2b, Recombinant (Intron A) in the Treatment of Chronic Hepatitis C in Patients Co-Infected and Concurrently Being Treated for HIV-1 Infection. Roerig Pharmaceuticals, August, 1993.
13. Co-Investigator: A Pilot Study of the Safety and Efficacy of the Concurrent Administration of Interferon Alfa-2b, Recombinant (Intron A) and Stavudine 92'3'-didehydro-3'-deoxythymidine; d4T). Roerig Pharmaceuticals, November, 1993.
14. Co-Investigator: A Pilot Study of the Frequency of Intravenous Thrombosis Formation Associated with the use of Central Venous Catheters in Patients Infected with HIV-1. Center for Special Immunology, February, 1994.
15. Co-Investigator: An Evaluation of the Use of Duragesic In AIDS Patients Who Have Chronic Pain. Janssen Pharm., December, 1993.

16. Co-Investigator: Oral/Intravenous Azithromycin Treatment of Cryptosporidiosis in Patients Whose Disease has Not Been Controlled by Conventional Therapy; Pfizer, Inc., Protocol 066-167S, September, 1992.
17. Co-Investigator: A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients with CMV Retinitis Treated with Foscavir; Astra Pharmaceuticals, Protocol 93FOS31, January 1994.
18. Principle Investigator: 3TC Open Label Program for Patients Intolerant or Failing Standard Antiretroviral Therapies; Glaxo, Protocol NUCA3304
19. Principle Investigator: An Open-Label, Multicenter Study to Provide Expanded Access and Obtain Additional Safety Data for Serostim (mammalian cell-derived recombinant human growth hormone, r-hGH[m]) in the Treatment of Adults with Advanced AIDS Wasting; Serono Laboratories, Treatment IND, March 1995.
20. Principle Investigator: A Multiclinic, Double-Blind, Randomized, Eighteen-Month Study of HIV-1 Seropositive Patients to Compare the Efficacy and Safety of MK-639, 800 mg q8h, and Zidovudine, 200 mg q8h, Administered Concomitantly to MK-639 Alone and Zidovudine Alone; Merck Research Laboratories, Protocol 003, February 1995.
21. Principle Investigator: An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in Persons with Limited Venous Access; Syntex, Inc., Protocol GANS2224, January, 1995.
22. Principle Investigator: An Open-Label Study of the Safety of Oral Ganciclovir for Prevention of CMV Disease in People Infected with Human Immunodeficiency Virus; Syntex, Inc., Protocol GANS2648, January, 1995.
23. Co-Investigator: An Evaluation of the Use of Duragesic (fentanyl patches) in AIDS Patients with Chronic Pain; Janssen Pharmaceuticals, January 1994.
24. Principle Investigator: Interferon Alfa-2b (Intron A) for the Treatment of Chronic Hepatitis C Infection in Patients Co-Infected with HIV; Schering Laboratories.
25. Principle Investigator: Vistide (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients with AIDS; Gilead Sciences, Inc., Protocol GS-95-120, August 1995.
26. Principle Investigator: Compassionate Use of DaunoXome in Advanced Kaposi's Sarcoma; NeXstar, Inc., Protocol 103-16, July 1995.
27. Principle Investigator: An Open Label International Compassionate Treatment Program for the Use of Saquinavir (Ro 21-8959; Protease Inhibitor) either as Monotherapy or in Combination with Other Antiretroviral Drugs in Patients with Proven HIV Infection; Hoffmann-La Roche, LTD., Protocol Ro21-8959, July 1995.
28. Principle Investigator: A Noncomparative, Multisite, Open-Label, 48-Week Study to Monitor the Safety and Tolerability of MK-639 (Indinavir Sulfate) 800 Mg q8h Administered as Monotherapy or in Combination with Reverse Transcriptase Inhibitor Therapy for the Treatment of HIV-1 Infection in Advanced AIDS Patients (Patients with CD4 Counts \leq 50 cells/cu mm); Merck & Co., Inc., Protocol No. 99, September 1995.
29. Principal Investigator: A Multicenter, Randomized, Open-Label Phase II Study of Vesnarinone and Zidovudine in Combination and Alone in HIV-Infected Persons with CD4 Counts \leq 500 Cellul; Otsuka America Pharmaceutical, Inc., Study #22-95-502, February, 1996.
30. Principal Investigator: A Compassionate Use Study Of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome; Cellegene Corporation, Protocol W-002, August, 1995.

31. Principal Investigator: A Placebo-Controlled Evaluation of the Effect of Chronic Testosterone Replacement Therapy (Testoderm Testosterone Transdermal System) on Body Cell Mass and Body Weight in Hypogonadal Males with AIDS. ALZA Corporation; Protocol C-95-012, July 11, 1995.
32. Open-Label Compassionate Use of Nitazoxanide (NTZ) for the Treatment of Cryptosporidiosis in AIDS Patients. Unimed Pharmaceuticals, Inc., June 7, 1996.
33. Protocol 1100.859: An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (nevirapine) in Adult and Pediatric Patients With Progressive, Symptomatic HIV Disease. Boehringer Ingelheim Pharmaceuticals, Inc., March 14, 1996.
34. Delavirdine Mesylate Expanded Access Program for HIV-1 Infected Patients. Pharmacia & Upjohn Protocol U-90152S/T, July 22, 1996.
35. An Open Label Study of the Use of Azithromycin In Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy. Pfizer, Inc. Protocol 066-162, June 6, 1994.
36. SeroAIDS Investigators Database Study: A Prospective Patient Registry to Study the Management and Treatment of AIDS-Associated Catabolism/Weight Loss. Serono Laboratories, Inc., February 1997.
37. The Sustiva (efavirenz) Expanded Access Program. The Dupont Merck Pharmaceutical Company Protocol Number DMP 266-903, August 1, 1997.
38. The PREVEON (adefovir dipivoxil) Expanded Access Program for the treatment of patients with AIDS who have failed other antiretroviral therapy and have limited treatment options. Gilead Sciences, Inc. Protocol Number: GS-97-423, November 21, 1997.
39. ABT-378/r (ABT-378/ritonavir) Early Access Program. Abbott Laboratories. Protocol Number M99-046, September 21, 1999.
40. Expanded Access Program for Tenofovir Disoproxil Fumarate (Tenofovir DF) in the Treatment of HIV-1 Infected Patients Who have Limited Treatment Options. Gilead Sciences, Inc. Protocol GS-00-955, January 19, 2001.
41. A Phase III Open-Label Safety Study of T-20/Ro 29-9800 (HIV-1 Infusion Inhibitor) in Combination with Oral Antiretrovirals in Patients Who Are Unable To Construct a Viable Regimen. F Hoffman-La Roche Inc. Protocol T-20-305/NV16391, August 13, 2001.
42. Protocol Number MV 16812: Multicenter, Open-Label, Early Access Program of Fuzeon (Unfuviritide) (T-20/Ro29-9800, HIV-1 Fusion Inhibitor) in Combination with Free Choice Antiretroviral Regime to Assess Serious Adverse Events, Serious AIDS Defining Events, and Tolerability in Patients with Advanced HIV- Infection. Hoffman-La Roche Inc. Protocol T-20/ Ro29-9800, October 2002.
43. Atazanavir (BMS-232632) for HIV Infected Individuals: An Early Access Program. Bristol-Meyers Squibb, Protocol AI424900. August 21, 2002.
44. HIV Research Network: A Prospective Observational Database Evaluating the Treatment and Cost Utilization Associated with Management of Chronic HIV Infection. Study coordination by Johns Hopkins Medical Center and funding by the Agency for Healthcare Research and Quality and the U.S. Department of Health and Human Services, 1998.

LICENSES / CERTIFICATIONS

California Physician License
Missouri Physician License
Kansas Physician License
DEA License
Basic/Advanced Cardiac Life Support
FDA & I.D.S.A. Sponsored Clinical Trials Training Program

PROFESSIONAL SOCIETIES

American College of Physicians
American Society for Parental and Enteral Nutrition.
Kansas Medical Society
Johnson County Medical Society
International AIDS Society
American Academy of HIV Medicine
HIV Medicine Association